mProX™ Human CDK12 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Jason
Verified Customer
Cynthia
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 CDK12/13 inhibition results in selective cytotoxicity in NB cells and affects transcription elongation.
Human NB cells treated with THZ531 at escalating doses for 72 hours showed dose-response curves. Included as well were Kelly E9R cells, which exhibit a homozygous mutation at the Cys1039 THZ531-binding region in CDK1220.
Ref: Krajewska, Malgorzata, et al. "CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation." Nature communications 10.1 (2019): 1757.
Pubmed: 30988284
DOI: 10.1038/s41467-019-09703-y
Research Highlights
As a member of the cyclin-dependent kinase (CDK) family of serine/threonine protein kinases, cyclin-dependent kinase 12 (CDK12) controls transcriptional and post-transcriptional processes, which in turn affects a variety of cellular functions.
Lui, Goldie YL, Carla Grandori, and Christopher J. Kemp. "CDK12: an emerging therapeutic target for cancer." Journal of clinical pathology 71.11 (2018): 957-962.
Pubmed:
30104286
DOI:
10.1136/jclinpath-2018-205356
A growing therapeutic target, cyclin-dependent kinase 12 (CDK12) controls the transcription of DNA-damage response (DDR) genes.
Jiang, Baishan, et al. "Discovery and resistance mechanism of a selective CDK12 degrader." Nature chemical biology 17.6 (2021): 675-683.
Pubmed:
33753926
DOI:
10.1038/s41589-021-00765-y